Core Viewpoint - SELLAS Life Sciences Group, Inc. has announced the immediate exercise of existing warrants, resulting in gross cash proceeds of approximately $31.0 million for the purchase of up to 22,363,714 shares of common stock [1][2]. Group 1: Financial Transaction - The immediate exercise of the existing warrants will provide the company with gross cash proceeds of about $31.0 million [1]. - Investors exercising the existing warrants will receive new registered warrants to purchase the same number of shares at an exercise price of $2.00, which will be exercisable immediately and will expire five years from issuance [2]. - The transaction is expected to close on or about October 28, 2025, pending customary closing conditions [2]. Group 2: Advisory and Registration - A.G.P./Alliance Global Partners and Maxim Group LLC acted as financial advisors for this transaction [3]. - The offering is being made under an effective shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission [4]. Group 3: Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [7]. - The company's lead product candidate, GPS, targets the WT1 protein and has potential applications in treating a wide range of hematologic malignancies and solid tumors [7]. - SELLAS is also developing SLS009, a differentiated small molecule CDK9 inhibitor, which has shown a high response rate in AML patients with unfavorable prognostic factors [7]. Group 4: Upcoming Events - SELLAS will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders and company management to discuss the treatment landscape for acute myeloid leukemia [5].

Company Overview - SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [2] - The lead product candidate, GPS, targets the WT1 protein found in multiple tumor types and has potential as both a monotherapy and in combination with other therapies [2] - The company is also developing SLS009 (tambiciclib), a differentiated small molecule CDK9 inhibitor, which shows a high response rate in AML patients with unfavorable prognostic factors [2] Event Participation - Dr. Angelos Stergiou, President and CEO of SELLAS, will participate in the J.P. Morgan U.S. Opportunities Forum on November 12, 2025 [1] - The event will take place at the Kimpton EPIC Hotel in Miami, Florida, and will consist of 1x1 investor meetings [2]

Core Insights - BlackRock has acquired a 5.4% ownership stake in Sellas Life Sciences Group, amounting to 5,686,886 shares, granting it voting control in the company [1][2] - Sellas Life Sciences has shown strong stock performance, with a 38% increase in after-hours trading and a 100% year-to-date gain [2] - The company is making significant clinical progress, particularly with its lead candidate, galinpepimut-S (GPS), currently in a Phase 3 trial for acute myeloid leukemia (AML) [4][5] Company Overview - Sellas Life Sciences is a late-stage biotechnology firm focused on developing treatments for cancer, specifically AML [4] - The company has two key programs: galinpepimut-S (GPS) and SLS009 (tambiciclib), both targeting AML [5][6] Clinical Developments - The REGAL trial for GPS has shown promising results, with median survival exceeding 13.5 months, which is more than double the historical average for standard treatments [5] - SLS009 has demonstrated encouraging Phase 2 results and has received Fast Track and Orphan Drug designations from the FDA [6][7] Market Implications - BlackRock's investment indicates growing institutional confidence in Sellas's long-term potential, despite the inherent risks associated with biotech investments [7] - Future valuation of Sellas will likely depend on the outcomes of the REGAL trial, which could significantly impact the company's market position if early survival benefits are confirmed [8]

Core Insights - Biotech stocks experienced a significant after-hours rally, with SOPHiA GENETICS and SELLAS Life Sciences leading the gains due to positive announcements regarding upcoming data presentations [1][2]. Company Highlights - SOPHiA GENETICS (SOPH) saw its shares increase by nearly 10%, closing at $4.44 [3]. - SELLAS Life Sciences Group Inc. (SLS) shares rose by 3.5% to $2.07 after announcing the presentation of preclinical efficacy data for its CDK9 inhibitor, SLS009, at the ESMO Congress 2025 [2]. - Other notable biotech companies that experienced stock price increases include Ironwood Pharmaceuticals (up 6.76% at $1.58), Spectral AI (up 8.60% at $2.40), and Adverum Biotechnologies (up 7.21% at $4.46) [3].

Core Insights - Preclinical data supports SLS009 as a promising treatment for T-cell prolymphocytic leukemia (T-PLL), both as a monotherapy and in combination with venetoclax [1][2][3] Group 1: Efficacy of SLS009 - SLS009 demonstrated significant single-agent activity and improved overall survival in a patient-derived xenograft model of relapsed/refractory T-PLL, with survival times of 7.4 weeks for SLS009 monotherapy and 7.9 weeks for the combination with venetoclax, compared to 4.4 weeks for venetoclax alone [2][3] - The combination of SLS009 and venetoclax was well tolerated, indicating a favorable safety profile [2][3] Group 2: Research Presentation - The findings will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled for October 17-21, 2025, in Berlin, Germany [1][4] - The poster presentation is titled "CDK9 Inhibition Enhances Venetoclax Activity and Prolongs Survival in a T-PLL Patient-Derived Xenograft Model" [4] Group 3: Company Overview - SELLAS Life Sciences Group, Inc. is focused on developing novel therapies for various cancer indications, with SLS009 being a key candidate as a differentiated small molecule CDK9 inhibitor [5][6] - The company also has a lead product candidate, GPS, which targets the WT1 protein and has potential applications in multiple hematologic malignancies and solid tumors [5]

Core Insights - SELLAS Life Sciences Group, Inc. is hosting a virtual R&D Day on October 29, 2025, to discuss the treatment landscape for acute myeloid leukemia (AML) and the unmet medical needs in this area [1][2] Group 1: Event Details - The R&D Day will feature key opinion leaders and company management discussing the ongoing Phase 3 REGAL trial of GPS, with results expected by year-end [2] - An update on SLS009, a selective CDK9 inhibitor, will be presented, including recent Phase 2 data and plans for a new AML study starting in Q1 2026 [2] Group 2: Key Opinion Leaders - Dr. Omer Jamy is a principal investigator of the REGAL study and focuses on AML and related therapies [4] - Dr. Panagiotis Tsirigotis is an investigator in the REGAL trial, emphasizing cellular therapies and hematopoietic cell transplantation [5] - Dr. Philip Amrein specializes in leukemias and has conducted research with SLS009 [6] - Dr. Sharif Khan is involved in both the REGAL trial and the SLS009 clinical program, focusing on breakthrough therapies [7] Group 3: Company Overview - SELLAS is a late-stage clinical biopharmaceutical company developing novel therapies for various cancer indications, with GPS targeting the WT1 protein [8] - SLS009 is positioned as a potentially first-in-class CDK9 inhibitor, showing high response rates in AML patients with unfavorable prognostic factors [9]

Core Points - SELLAS Life Sciences Group, Inc. announced the immediate exercise of warrants to purchase up to 19,685,040 shares of common stock for gross cash proceeds of approximately $23.6 million [1][2] - The investor will receive new unregistered warrants at an exercise price of $1.88, which will be exercisable immediately and will expire in five years and six months [2] - The transaction is expected to close on or about September 12, 2025, subject to customary closing conditions [2] Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [6] - The lead product candidate, GPS, targets the WT1 protein present in multiple tumor types and has potential as both a monotherapy and in combination with other therapies [6] - The company is also developing SLS009, a differentiated small molecule CDK9 inhibitor, which has shown a high response rate in AML patients with unfavorable prognostic factors [6]

Core Insights - Solaris Resources Inc. has signed a landmark agreement with the Pueblo Shuar Arutam organization, enhancing its social engagement efforts and supporting the Warintza Project in Ecuador [2][3] - The agreement establishes formal relationships with all Indigenous organizations surrounding the Warintza Project, reinforcing the company's commitment to community-led development [3][4] Social Engagement and Partnerships - The agreement with PSHA, representing nearly 10,000 people organized into 47 Shuar centers, follows a Letter of Intent signed in February 2025 and builds on previous partnerships with local Shuar centers [3][4] - Solaris has also established a trilateral cooperation agreement with the Interprovincial Federation of Shuar Centers and a partnership with the Alliance for Entrepreneurship and Innovation of Ecuador, creating a strong social foundation for the Warintza Project [4] Project Development and De-Risking Initiatives - Solaris is advancing critical de-risking initiatives essential for the Warintza Project's development timeline, including the submission of the Technical Environmental Impact Assessment [5][6] - The final Technical EIA report has been submitted and is currently under government review, following positive engagement with Ecuador's Ministry of Environment and Energy [6][8] - A site visit by government officials in July 2025 marked progress towards the Free, Prior and Informed Consultation process, which is expected to commence in the coming months [7][8] Pre-Feasibility Study and Resource Estimates - The Warintza Pre-Feasibility Study is progressing with positive momentum, incorporating an updated Mineral Resource Estimate that includes resources from Warintza West, expected to be completed in the second half of 2025 [9][10] - Solaris is focused on long-term value creation and aims for a Final Investment Decision, supported by strengthened community partnerships and a reinforced financial position following a recent transaction with Royal Gold [10][11] Exploration Opportunities - Beyond the defined Mineral Resource Estimate, Solaris is pursuing high-impact exploration opportunities within the broader Warintza district, which is considered highly prospective and underexplored [11][12]

Company Overview - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a clinical-stage biopharmaceutical company focused on developing cancer therapies, particularly for hematologic malignancies [1] - The company's pipeline includes two candidates: Galinpepimut-S (GPS) and SLS009 (tambiciclib) [1] Product Pipeline - Galinpepimut-S (GPS) is an immunotherapy currently in Phase 3 clinical trials for acute myeloid leukemia (AML) [1] - SLS009 (tambiciclib) is another candidate in the company's pipeline, although specific details about its development stage are not provided [1]

[Corporate Highlights & Pipeline Update](index=1&type=section&id=Corporate%20Highlights%20%26%20Pipeline%20Update) SELLAS advanced its AML pipeline with positive SLS009 Phase 2 results and a positive IDMC recommendation for REGAL [Phase 3 REGAL Trial of GPS](index=1&type=section&id=Phase%203%20REGAL%20Trial%20of%20GPS) The IDMC recommended continuing the Phase 3 REGAL trial for GPS in AML, with final data expected by year-end 2025 - The IDMC issued a positive recommendation to continue the Phase 3 REGAL trial of GPS in AML without modification, identifying no safety concerns[5](index=5&type=chunk) - The final analysis of the REGAL trial is expected by year-end 2025, contingent on reaching 80 patient deaths[5](index=5&type=chunk) [Phase 2 Trial of SLS009 in r/r AML](index=1&type=section&id=Phase%202%20Trial%20of%20SLS009%20in%20r%2Fr%20AML) The Phase 2 SLS009 trial in r/r AML met all primary endpoints, showing a **44% response rate** and **8.9-month mOS** in AML-MRC patients - The trial met all primary endpoints, with a **44% response rate** in patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML-MRC), exceeding the 20% target[7](index=7&type=chunk) - Median overall survival (mOS) was **8.9 months** in AML-MRC patients and **8.8 months** in patients refractory to venetoclax-based regimens, far exceeding the historical benchmark of **2.4 months**[7](index=7&type=chunk) [SLS009 Future Development](index=2&type=section&id=SLS009%20Future%20Development) The FDA recommended advancing SLS009 into a first-line AML trial, with an **80-patient study** planned for Q1 2026 enrollment - The FDA recommended advancing SLS009 into a trial for newly diagnosed, first-line AML patients eligible for venetoclax/azacitidine therapy[8](index=8&type=chunk) - An **80-patient randomized trial** is being prepared, with enrollment expected to start by **Q1 2026**, potentially supporting an NDA and accelerated approval[8](index=8&type=chunk) [Other Corporate Developments](index=2&type=section&id=Other%20Corporate%20Developments) SELLAS presented positive preclinical data for SLS009, expanded its Scientific Advisory Board, and was included in Russell Indexes - Presented preclinical data at ASCO 2025 showing SLS009's efficacy in ASXL1 mutated colorectal cancer[9](index=9&type=chunk) - Expanded the Scientific Advisory Board with three new members: Philip C. Amrein, MD, Alex Kentsis, MD, PhD, and Linghua Wang, MD, PhD[10](index=10&type=chunk) - Announced inclusion in the Russell 3000® and Russell 2000® Indexes[11](index=11&type=chunk) - A poster on the preclinical efficacy of SLS009 in T-Cell Prolymphocytic Leukemia (T-PLL) will be presented at ESMO 2025[12](index=12&type=chunk) [Financial Results for the Second Quarter 2025](index=3&type=section&id=Financial%20Results%20for%20the%20Second%20Quarter%202025) SELLAS reported a reduced net loss of **$6.6 million** in Q2 2025, driven by lower R&D expenses, ending with **$25.3 million** in cash [R&D Expenses](index=3&type=section&id=R%26D%20Expenses) Research and development expenses decreased to **$3.9 million** in Q2 2025, primarily due to reduced clinical trial costs R&D Expenses Comparison (in millions) | Period | 2025 | 2024 | | :--- | :--- | :--- | | **Q2** | $3.9 | $5.2 | | **H1** | $7.1 | $10.3 | [G&A Expenses](index=3&type=section&id=G%26A%20Expenses) General and administrative expenses increased to **$3.0 million** in Q2 2025, driven by higher professional fees and personnel costs G&A Expenses Comparison (in millions) | Period | 2025 | 2024 | | :--- | :--- | :--- | | **Q2** | $3.0 | $2.4 | | **H1** | $5.9 | $7.0 | [Net Loss](index=3&type=section&id=Net%20Loss) Net loss decreased to **$6.6 million** (or **$0.07 per share**) in Q2 2025, an improvement from **$7.5 million** in Q2 2024 Net Loss and Loss Per Share Comparison | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | **Net Loss (in millions)** | $6.6 | $7.5 | $12.4 | $17.0 | | **Loss Per Share** | $0.07 | $0.13 | $0.13 | $0.33 | [Cash Position](index=3&type=section&id=Cash%20Position) Cash and cash equivalents totaled **$25.3 million** as of June 30, 2025, with an additional **$4.0 million** from warrant exercises - Cash and cash equivalents totaled **$25.3 million** as of June 30, 2025[16](index=16&type=chunk) - The company received an additional **$4.0 million** in proceeds from warrant exercises in July 2025[16](index=16&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section presents SELLAS Life Sciences' unaudited consolidated Statements of Operations and Balance Sheets for Q2 2025 [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Total operating expenses were **$6.9 million** and net loss was **$6.6 million** for Q2 2025, an improvement from Q2 2024 Consolidated Statements of Operations (Unaudited, in thousands) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Research and development (in thousands)** | $3,871 | $5,186 | $7,076 | $10,297 | | **General and administrative (in thousands)** | $3,002 | $2,435 | $5,860 | $6,969 | | **Total operating expenses (in thousands)** | $6,873 | $7,621 | $12,936 | $17,266 | | **Loss from operations (in thousands)** | $(6,873) | $(7,621) | $(12,936) | $(17,266) | | **Interest income (in thousands)** | $272 | $151 | $522 | $230 | | **Net loss (in thousands)** | **$(6,601)** | **$(7,470)** | **$(12,414)** | **$(17,036)** | | **Net loss per share, basic and diluted (in dollars)** | $(0.07) | $(0.13) | $(0.13) | $(0.33) | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) Total assets were **$32.3 million** and total stockholders' equity was **$26.1 million** as of June 30, 2025, a significant increase Consolidated Balance Sheet Highlights (Unaudited, in thousands) | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents (in thousands)** | $25,297 | $13,886 | | **Total current assets (in thousands)** | $29,447 | $16,327 | | **Total assets (in thousands)** | **$32,305** | **$19,432** | | **Total current liabilities (in thousands)** | $5,999 | $9,510 | | **Total liabilities (in thousands)** | $6,156 | $9,967 | | **Total stockholders' equity (in thousands)** | **$26,149** | **$9,465** | | **Total liabilities and stockholders' equity (in thousands)** | **$32,305** | **$19,432** | [About SELLAS and Forward-Looking Statements](index=4&type=section&id=About%20SELLAS%20and%20Forward-Looking%20Statements) SELLAS is a late-stage biopharmaceutical company developing cancer therapies, with forward-looking statements subject to risks - SELLAS is a late-stage biopharmaceutical company developing cancer therapies, with lead candidates GPS (targeting WT1 protein) and SLS009 (a CDK9 inhibitor)[17](index=17&type=chunk) - The report includes forward-looking statements concerning clinical development, timing of milestones, and potential regulatory approvals, which are subject to inherent risks and uncertainties[18](index=18&type=chunk)